Elan closes offices in New York and Tokyo
This article was originally published in Scrip
Executive Summary
Elanis to close its offices in New York and Tokyo and cut 114 positions early next year to direct more cash to its pipeline. The company said that it will also make adjustments to its commercial activities in Tysabri (natalizumab) for Crohn's disease. Tysabri, Elan's lead product, performed well in the third quarter, more than doubling in in-market net sales to $237 million. However, analysts still have little confidence in the drug given the cases of progressive multifocal leucoencephalopathy that have been confirmed in patients receiving Tysabri (Scrip Online, October 24th, 2008). Elan, which employs around 1,700 workers globally, will now shift its focus from a traditional sales and commercial model to a model based on clinical support and education, Dr Carlos Paya, the company's president said.
You may also be interested in...
Myotec and Hybrid merge to form PsiOxus
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
Trophos's MitoCare programme receives €6 million EU funding
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Novartis and Alcon reach compromise to settle merger saga
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.